HIV-1-specific immunity in persistently seronegative individuals at high risk for HIV infection-Reference-Cited by-同舟云学术

HIV-1-specific immunity in persistently seronegative individuals at high risk for HIV infection

Published:1996-06 Issue:1-2 Volume:51 Page:39-43
ISSN:0165-2478
Container-title:Immunology Letters
language:en
Short-container-title:Immunology Letters

Author:

Beretta Alberto,Furci Lucinda,Burastero Samuele,Cosma Antonio,Dinelli Maria Elena,Lopalco Lucia,De Santis Claudio,Tambussi Giuseppe,Carrow Emily,Sabbatani Sergio,Clerici Mario,Lazzarin Adriano,Siccardi Antonio G.

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference24 articles.

1. Multifactorial Nature of Human Immunodeficiency Virus Disease: Implications for Therapy

2. T-cell response towards HIV in infected individuals with and without zidovudine therapy, and in HIV-exposed sexual partners

3. Lymphocyte Proliferative Responses to HIV-1 Envelope and Core Antigens by Infected and Uninfected Adults and Children

4. Exposure to Human Immunodeficiency Virus Type I-Specific T Helper Cell Responses before Detection of Infection by Polymerase Chain Reaction and Serum Antibodies

5. Cell-Mediated Immune Response to Human Immunodeficiency Virus (HIV) Type 1 in Seronegative Homosexual Men with Recent Sexual Exposure to HIV-1

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunization with HIV-1 trimeric SOSIP.664 BG505 or founder virus C (FVCEnv) covalently complexed to two-domain CD4S60C elicits cross-clade neutralizing antibodies in New Zealand white rabbits;Vaccine: X;2022-12

2. NK Cells in Protection from HIV Infection;Viruses;2022-05-25

3. A novel HIV vaccine targeting the protease cleavage sites;AIDS Research and Therapy;2017-09-12

4. An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques;Clinical and Vaccine Immunology;2016-07

5. Innate Activation of MDC and NK Cells in High-Risk HIV-1–Exposed Seronegative IV-Drug Users Who Share Needles When Compared With Low-Risk Nonsharing IV-Drug User Controls;JAIDS Journal of Acquired Immune Deficiency Syndromes;2015-03-01